Contrasting Virios Therapeutics (NASDAQ:VIRI) and Antibe Therapeutics (OTCMKTS:ATBPF)

Virios Therapeutics (NASDAQ:VIRI) and Antibe Therapeutics (OTCMKTS:ATBPF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Earnings & Valuation

This table compares Virios Therapeutics and Antibe Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30 million	($0.27)	-17.85
Antibe Therapeutics	N/A	N/A	-$14.73 million	($0.25)	-0.86

Virios Therapeutics is trading at a lower price-to-earnings ratio than Antibe Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

9.1% of Virios Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Antibe Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Virios Therapeutics and Antibe Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Antibe Therapeutics	N/A	-56.48%	-29.07%

Analyst Recommendations

This is a summary of current ratings for Virios Therapeutics and Antibe Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0	1	0	0	2.00
Antibe Therapeutics	0	0	0	0	0.00

Virios Therapeutics presently has a consensus target price of $5.00, suggesting a potential upside of 3.73%. Given Virios Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Virios Therapeutics is more favorable than Antibe Therapeutics.

Volatility and Risk

Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, Antibe Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Summary

Virios Therapeutics beats Antibe Therapeutics on 6 of the 10 factors compared between the two stocks.

About Virios Therapeutics

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

About Antibe Therapeutics

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.